Mithramycin for Lung, Esophagus, and Other Chest Cancers
Terminated
National Cancer Institute (NCI)
Phase 2
2012-09-06
Background:
- Mithramycin is a drug that was first tested as a cancer therapy in the 1960s. It acted
against some forms of cancer, but was never accepted as a treatment. Research suggests that
it may be useful against some cancers of the chest, such as lung and esophageal cancer or
mesothelioma. Researchers want to see if mithramycin can be used to treat these types of
cancer.
Objectives:
- To see if mithramycin is safe and effective against different chest cancers.
Eligibility:
- Individuals at least 18 years of age who have lung, esophagus, pleura, or mediastinum
cancers.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected. Imaging studies and tumor tissue samples will be used to
monitor the cancer before treatment.
- Participants will receive mithramycin every day for 7 days, followed by 7 days without
treatment. Each 14-day round of treatment is called a cycle.
- Treatment will be monitored with frequent blood tests and imaging studies.
- Participants will continue to take the drug for as long as the side effects are not
severe and the tumor responds to treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
